Provided by Tiger Trade Technology Pte. Ltd.

DiaMedica Therapeutics Inc.

6.84
-0.0200-0.29%
Volume:40.93K
Turnover:280.34K
Market Cap:366.48M
PE:-9.55
High:7.01
Open:6.77
Low:6.77
Close:6.86
52wk High:10.42
52wk Low:3.19
Shares:53.58M
Float Shares:32.94M
Volume Ratio:0.41
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7162
EPS(LYR):-0.6050
ROE:-64.12%
ROA:-38.33%
PB:7.10
PE(LYR):-11.31

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call

Reuters
·
Mar 23

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

THOMSON REUTERS
·
Mar 23

DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
Mar 13

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC)

TIPRANKS
·
Mar 09

DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study

TIPRANKS
·
Mar 05

Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial

Reuters
·
Mar 05

DiaMedica Therapeutics Inc - to Initiate Phase 2 Dm199 Trial in 2026; US and UK Expansion Planned

THOMSON REUTERS
·
Mar 05

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of Dm199 in Preeclampsia

THOMSON REUTERS
·
Mar 05

DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences

Reuters
·
Feb 24

DiaMedica Therapeutics Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Jan 17

BRIEF-Diamedica Therapeutics Provides Dm199 Preeclampsia Program Update

Reuters
·
Dec 18, 2025

DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting

Reuters
·
Dec 18, 2025

DiaMedica Therapeutics Inc - FDA Requests Additional Non-Clinical Study for Dm199

THOMSON REUTERS
·
Dec 18, 2025

DiaMedica Therapeutics Provides Dm199 Preeclampsia Program Update Following Pre-Ind Meeting With FDA

THOMSON REUTERS
·
Dec 18, 2025

10% Owner Jan Stahlberg Reports Acquisition of Common Shares of DiaMedica Therapeutics Inc

Reuters
·
Dec 09, 2025

Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)

TIPRANKS
·
Nov 14, 2025

Diamedica Therapeutics (DMAC) Initiated with a Buy at Cantor Fitzgerald

TIPRANKS
·
Nov 14, 2025

DiaMedica Therapeutics Q3 Cash & Investments USD 55.3 Million

THOMSON REUTERS
·
Nov 13, 2025

DiaMedica Therapeutics Q3 Net Income USD -8.62 Million

THOMSON REUTERS
·
Nov 13, 2025